- Home
- PCVX vs AFRM Comparison
PCVX vs AFRM Comparison
Compare PCVX & AFRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | AFRM |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 19.6B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PCVX | AFRM |
|---|---|---|
| Price | $61.38 | $46.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 29 |
| Target Price | ★ $98.33 | $83.65 |
| AVG Volume (30 Days) | 1.5M | ★ 7.4M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 108.98 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $3,224,412,000.00 |
| Revenue This Year | N/A | $30.35 |
| Revenue Next Year | N/A | $24.53 |
| P/E Ratio | ★ N/A | $83.97 |
| Revenue Growth | N/A | ★ 38.80 |
| 52 Week Low | $28.09 | $30.90 |
| 52 Week High | $76.61 | $100.00 |
Technical Indicators
Market Signals| Indicator | PCVX | AFRM |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 29.38 |
| Support Level | $42.30 | $45.54 |
| Resistance Level | N/A | $79.27 |
| Average True Range (ATR) | 3.27 | 3.25 |
| MACD | 0.36 | -0.08 |
| Stochastic Oscillator | 72.47 | 4.36 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About AFRM Affirm Holdings Inc.
Founded in 2012, Affirm is a market leader in the buy-now, pay-later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also comprise the majority of its revenue. Affirm primarily operates in the United States, which accounted for more than 95% of its revenue in 2025, but the firm has also expanded to Canada and the United Kingdom.